Sugi Predict

Sugi Predict / Compounds / SCHEMBL1128764

SCHEMBL1128764

SCHEMBL1128764

OCc1cccc2cccc(Br)c12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ CYP1A1 P04798 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CYP1B1 Q16678 1/20 0.36
▸ APOBEC3G Q9HC16 1/20 0.35
▸ CNR2 P34972 3/20 0.35
▸ THRB P10828 1/20 0.34
▸ TAAR1 Q96RJ0 1/20 0.34
▸ PDCD1 Q15116 1/20 0.34
▸ CD274 Q9NZQ7 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ ACP3 P15309 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384962 0.84 CYP1A2 (0.45) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL27015 0.84 CYP1A2 (0.45) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL29876215 0.83 HTR2A (0.40) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL23043093 0.83 HTR2A (0.40) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL23043210 0.80 HTR2A (0.38) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL23043517 0.80 TSHR (0.38) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL29681001 0.80 TSHR (0.38) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1
SCHEMBL25323955 0.79 HTR2A (0.37) CYP1A2ALDH1A1HPGDHSD17B10TSHR
SCHEMBL29428571 0.79 HTR2A (0.37) CYP1A2ALDH1A1HPGDHSD17B10TSHR
SCHEMBL24536469 0.78 ALDH1A1 (0.36) CYP1A2ALDH1A1HPGDHSD17B10CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1046528-A As the new naphthalane base-3H-1 of antihyperglycemic agents, 2,3,5-oxygen thia diazole 2-oxide compound AMERICAN HOME PROD (US) 1990-10-31 — — CN claimed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-12398154-B2 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2025-08-26 — — US disclosed
US-20240309020-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2024-09-19 — — US disclosed
CN-111989321-B KRAS G12C inhibitors 米拉蒂治疗股份有限公司 2024-05-14 — — CN disclosed
US-11964989-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2024-04-23 — — US disclosed
CN-114615981-B KRAS G12D inhibitors 米拉蒂治疗股份有限公司 2024-04-12 — — CN disclosed
US-20240101553-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2024-03-28 — — US disclosed
US-20230373999-A1 KRAS G12C INHIBITORS MIRATI THERAPEUTICS INC (US) 2023-11-23 — — US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 — — US disclosed
US-8957049-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-02-17 — — US disclosed
WO-2014141043-A1 PROCESS AND DEVICE FOR THE COLORIMETRIC DETECTION OR ASSAYING OF TRACES OF TOXIC ORGANIC COMPOUNDS IN THE AIR COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-09-18 — — WO disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 — — US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 — — US disclosed
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. 2011-07-14 — — US disclosed
CN-102046179-A Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS INC 2011-05-04 — — CN disclosed
EP-2282742-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2011-02-16 — — EP disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 — — WO disclosed
WO-2009126691-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC (US) 2009-10-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172186-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CYP1A2 207/4885ALDH1A1 354/4885HPGD 189/4885
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS CYP1A2 4159/4885ALDH1A1 1816/4885HPGD 968/4885
US-20240101553-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP1A2 4667/4885ALDH1A1 3370/4885HPGD 1741/4885
US-11964989-B2 KRas G12D inhibitors KRAS, NRAS, HRAS CYP1A2 4709/4885ALDH1A1 1957/4885HPGD 823/4885
US-12398154-B2 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS CYP1A2 4465/4885ALDH1A1 4127/4885HPGD 1606/4885
US-20250388606-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS CYP1A2 3852/4885ALDH1A1 3580/4885HPGD 2815/4885
US-20240309020-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS CYP1A2 4446/4885ALDH1A1 2681/4885HPGD 749/4885
US-20230373999-A1 KRAS G12C INHIBITORS KRAS, NRAS, HRAS CYP1A2 4667/4885ALDH1A1 3370/4885HPGD 1741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.